Figure 3.
COPD exacerbations in the TRILOGY study.
Notes: Unadjusted annual rate of COPD exacerbations of differing severity in the intent-to-treat population for the TRILOGY study. Reprinted from The Lancet, 388(10048), Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial, Pages 963–973, Copyright 2016, with permission from Elsevier.81
Abbreviations: BDP, beclomethasone dipropionate; FF, fluticasone furoate; GB, glycopyrronium bromide.